MEDIPOST has been recognized as the “winner” in stem cell technologies by HSBC.

In an analysis report titled “Disruptive Technologies,”the multinational bank’s global research center said the Seoul-based company is “investible”as it has regulator-approved stem cell treatment, sales network and is well funded.

The center defined “disruptive technology” as any innovation that is liable to revolutionize an industry and challenge the dominance of its incumbents.

In 2012, MEDIPOST earned approval from the Korea Food and Drug Administration to sell CARTISTEM^®, a somatic stem cell-based therapy for knee cartilage defects caused by degeneration or repeated trauma.

Noting that Korea’s bio firms are exploiting not only stem cells’ ability to regenerate new cells in damaged areas, but also their paracrine effects for therapeutic purposes, the center said MEDIPOST’s NEUROSTEM-AD for Alzheimer’s disease is an example of the latter.

The center forecasts the global stem cell market to reach roughly $88 billion by 2014, up from $4.3 billion last year.

pss@koreatimes.co.kr